Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso treatments, such as Roche and Astellas' Tarceva (erlotinib), AZ's Iressa (gefitinib) and Boehringer Ingelheim's Giotrif (afatinib).

Boehringer stops Gilotrif head and neck cancer trials

Boehringer stops Gilotrif head and neck cancer trials It is already vying in the marketplace against AstraZeneca's Iressa (gefitinib) and Roche/Astellas' Tarceva (erlotinib) in first-line NSCLC, and looks likely to face increased pressure with the availability

Astellas promotes John Demaree

Astellas promotes John Demaree Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

Roche gets EU okay for Avastin/Tarceva combination

Roche gets EU okay for Avastin/Tarceva combination Avastin targets VEGF while Tarceva is an EGFR inhibitor - pathways known to be drivers of tumour growth - and both are already approved individually as NSCLC therapies. ... Patients given the combination lived without disease progression for a median of

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer The two-stage trial of patritumab (U3-1287/AMG 888) in combination with Roche's EGFR inhibitor Tarceva (erlotinib) patients with non-small cell lung cancer (NSCLC) was stopped on the

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics